Bioventus is partnering with Blue Cross Blue Shield of Michigan to provide its knee osteoarthritis treatments to Medicare Advantage and Commercial patients, beginning Jan. 1, 2020.
Three things to know:
1. The arrangement includes Bioventus' Durolane, Gelsyn-3 and Supartz FX hyaluronic acid-based treatments for knee OA.
2. Durolane is a single-injection, Gelsyn-3 is a three-injection, and Supartz FX is a five-injection joint fluid treatment.
3. Earlier this year Bioventus signed a nationwide contract with UnitedHealthcare to make Durolane and Gelsyn-3 available to employer and individual commercial plans, starting Oct. 1.